Overview

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine whether a initial combination of linagliptin and metformin compared to linagliptin alone for 24 weeks is effective in newly diagnosed, treatment-naïve patients with Type 2 Diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
Boehringer Ingelheim
Collaborator:
Eli Lilly and Company
Treatments:
Linagliptin
Metformin